High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer

Journal of Ovarian Research

Volumn 5, Issue 1, 2012, Pages

  Kalapotharakos, Grigorios ^a   Asciutto, Christine ^a   Henic, Emir ^a   Casslén, Bertil ^a   Borgfeldt, Christer ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

HE4; Ovarian neoplasm; Prognosis; ROMA; Survival analyses

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; PACLITAXEL; PLATINUM;

ADULT; ALGORITHM; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURGERY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; POSTMENOPAUSE; PREDICTOR VARIABLE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 84865071868     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-5-20     Document Type: Article

References (27)

1. CA125 antigen levels in obstetric and gynecologic patients. Niloff JM, Knapp RC, Schaetzl E, Reynolds C, Bast RC Jr, Obstet Gynecol 1984 64 703 707 6208522
2. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Drapkin R, von Horsten HH, Lin Y, et al. Cancer Res 2005 65 2162 2169 10.1158/0008-5472.CAN-04- 3924 15781627
3. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Hellstrom I, Hellstrom KE, Adv Exp Med Biol 2008 622 15 21 10.1007/978-0-387-68969-2-2 18546615
4. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Moore RG, Brown AK, Miller MC, et al. Gynecol Oncol 2008 110 196 201 10.1016/j.ygyno.2008.04.002 18495222
5. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Moore RG, McMeekin DS, Brown AK, et al. Gynecol Oncol 2009 112 40 46 10.1016/j.ygyno.2008.08.031 18851871
6. The revised American Fertility Society classification of endometriosis: reproducibility of scoring. Rock JA, ZOLADEX Endometriosis Study Group. Fertil Steril 1995 63 1108 1110
7. Prediction of pregnancy in infertile women based on the American Society for Reproductive Medicine's revised classification of endometriosis. Guzick DS, Silliman NP, Adamson GD, et al. Fertil Steril 1997 67 822 829 10.1016/S0015-0282(97)81392-1 9130885
8. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Andersen MR, Goff BA, Lowe KA, et al. Gynecol Oncol 2010 116 378 383 10.1016/j.ygyno.2009.10.087 19945742
9. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Hellstrom I, Raycraft J, Hayden-Ledbetter M, et al. Cancer Res 2003 63 3695 3700 12839961
10. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery. Scholler N, Garvik B, Hayden-Ledbetter M, Kline T, Urban N, Cancer Lett 2007 247 130 136 10.1016/j.canlet.2006.03.029 16677756
11. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. Montagnana M, Lippi G, Ruzzenente O, et al. J Clin Lab Anal 2009 23 331 335 10.1002/jcla.20340 19774626
12. Usefulness of serum HE4 in endometriotic cysts. Montagnana M, Lippi G, Danese E, Franchi M, Guidi GC, Br J Cancer 2009 101 548 10.1038/sj.bjc.6605119 19513069
13. Systematic evaluation of candidate blood markers for detecting ovarian cancer. Palmer C, Duan X, Hawley S, et al. PLoS One 2008 3 2633 10.1371/journal.pone.0002633 18612378
14. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Van Gorp T, Cadron I, Despierre E, et al. Br J Cancer 2011 104 863 870 10.1038/sj.bjc.6606092 21304524
15. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Moore RG, Jabre-Raughley M, Brown AK, et al. Am J Obstet Gynecol 2010 203 228 e1-6. 20471625
16. Population-based cohort follow-up study of all patients operated for borderline ovarian tumor in western Sweden during an 11-year period. Akeson M, Zetterqvist BM, Dahllof K, Jakobsen AM, Brannstrom M, Horvath G, Int J Gynecol Cancer 2008 18 453 459 10.1111/j.1525-1438.2007.01051.x 18476948
17. Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Suh-Burgmann E, Gynecol Oncol 2006 103 841 847 10.1016/j.ygyno.2006.05.014 16793124
18. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Huhtinen K, Suvitie P, Hiissa J, et al. Br J Cancer 2009 100 1315 1319 10.1038/sj.bjc.6605011 19337252
19. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Molina R, Escudero JM, Auge JM, et al. Tumour Biol 2011 32 1087 1095 10.1007/s13277-011-0204-3 21863264
20. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Paek J, Lee SH, Yim GW, et al. Eur J Obstet Gynecol Reprod Biol 2011 158 338 342 10.1016/j.ejogrb.2011.05.021 21683503
21. Neoadjuvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study. Ansquer Y, Leblanc E, Clough K, et al. Cancer 2001 91 2329 2334 10.1002/1097-0142(20010615)91:12<2329::AID-CNCR1265>3.0.CO;2-U 11413522
22. Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Mazzeo F, Berliere M, Kerger J, et al. Gynecol Oncol 2003 90 163 169 10.1016/S0090- 8258(03)00249-X 12821358
23. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Schmeler KM, Sun CC, Bodurka DC, et al. Gynecol Oncol 2008 108 510 514 10.1016/j.ygyno.2007.11.013 18155273
24. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ, J Clin Oncol 2002 20 1248 1259 10.1200/JCO.20.5.1248 11870167
25. Survival and prognostic factors in patients with ovarian cancer. Tingulstad S, Skjeldestad FE, Halvorsen TB, Hagen B, Obstet Gynecol 2003 101 885 891 10.1016/S0029-7844(03)00123-6 12738145
26. Micropapillary serous ovarian carcinoma: surgical management and clinical outcome. Bristow RE, Gossett DR, Shook DR, et al. Gynecol Oncol 2002 86 163 170 10.1006/gyno.2002.6736 12144823
27. Role of Extended Chemotherapy in Advanced Ovarian Cancer Patients with High Posttreatment Serum CA-125 Levels. Kang S, Kim TJ, Seo SS, Kim BG, Bae DS, Park SY, Gynecol Obstet Invest 2011 72 50 54 10.1159/000322438 21372548